Randy Vogenberg, PhD, RPh, a nationally recognized expert and benefits author, covers the landscape of biologic and specialty pharmacy product coverage as well as benefit design issues.
-
Specialty Pharmacy & Biologics -
Selling Into Health PlansVideo: Organizations selling into health plans or delivery systems in different US markets may be facing unknown changes among key stakeholders or not fully understand the current or emerging interrelationships among the key players in a geographic area.
-
Specialty Pharmacy and Biologics ResearchVideo: Biologics and specialty pharmacy are the fastest growing segment of the pharmaceutical portion of the healthcare dollar
-
Retail Health ClinicsVideo: Learn about the trends affecting the Retail Health Clinics market.
Knowledge Source Reports
Group Purchasing Organizations 2011
Knowledge Source’s report Group Purchasing Organizations (GPO) Market Overview 2011 examines the competitive landscape of the group purchasing industry. The latest trends in the market are identified and 75 of the leading market participants in this sector are profiled.
Hepatitis C and Pittsburgh MSA
In the United States, an estimated 3.2 million Americans are living with chronic hepatitis C virus (HCV). There is a long latent period that can span 20 to 30 years. This means that many of the baby boomer population could show signs or symptoms of HCV.
Oncology and Boston MSA
Specialty pharmaceutical products and services are increasingly employed in the management of complex and chronic disease patients. Their effective adoption requires knowing and acting on the inter-relationships among each specific geographic region’s market stakeholders/players.
Knowledge Blogs
Express Scripts seems to have won the year-long battle with Catalyst Rx
Randy Vogenberg, PhD, RPh, a nationally recognized expert and benefits author, covers the landscape of biologic and specialty pharmacy product coverage as well as benefit design issues.
Drug sales handled by drug wholesalers increased to 87% in 2010 from 82% in 2007
Veterans Affairs $32 billion drug contract remains undecided
